14:23 , Mar 20, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Dermira, resTORbio, NanoString

Dermira raised $130 million in an upsized offering that followed closely after its eczema readout this week, while resTORbio and NanoString also priced follow-ons late Tuesday. Dermira Inc. (NASDAQ:DERM) sold 9.8 million shares at $13.25,...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
16:50 , Jul 20, 2018 |  BC Week In Review  |  Financial News

NanoString prices follow-on, reports preliminary earnings

Molecular diagnostic company NanoString Technologies Inc. (NASDAQ:NSTG) raised $50 million on July 17 through the sale of 4 million shares at $12.50 in a follow-on underwritten by J.P. Morgan, UBS Investment Bank and Baird. The...
23:07 , Jul 17, 2018 |  BC Extra  |  Financial News

NanoString prices follow-on, reports preliminary earnings

Molecular diagnostic company NanoString Technologies Inc. (NASDAQ:NSTG) raised $50 million through the sale of 4 million shares at $12.50 in a follow-on underwritten by J.P. Morgan, UBS Investment Bank and Baird. The price is a...
02:17 , Jun 9, 2018 |  BioCentury  |  Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago....
19:16 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

OncoSec reports preliminary Phase I data for ImmunoPulse IL-12 in TNBC

OncoSec Medical Inc. (NASDAQ:ONCS) reported preliminary data from two evaluable heavily pretreated patients with metastatic triple-negative breast cancer (TNBC) in the Phase I OMS-I140 trial showing that a single cycle of intratumoral ImmunoPulse IL-12 (OMS...
23:36 , Jan 17, 2018 |  BC Extra  |  Company News

Management tracks: NanoString, Orchard

Molecular diagnostics company NanoString Technologies Inc. (NASDAQ:NSTG) hired Thomas Bailey as CFO. He was CFO of AgaMatrix Holdings LLC (Salem, N.H.). Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) hired Frank Thomas as CFO and...
23:21 , Jan 9, 2018 |  BC Extra  |  Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
20:45 , Dec 22, 2017 |  BioCentury  |  Product Development

Beyond PD-L1 assays

Data from Genentech Inc.’s Phase III IMpower150 trial of Tecentriq atezolizumab in first-line non-small cell lung cancer provides the company with its first hard data showing what work lies ahead before it will be ready...